The executive vice president of the Foundation for Medical Research and Innovation of Sanitas Hospitals, Sonia Gutiérrez, has announced the latest advances achieved in clinical trials. These progresses, as pointed out by the head of the Hematology Service of the Blua Sanitas La Moraleja Hospital in Madrid, Dr. José Francisco Tomás, translate into patients being able to access new treatments sooner, given that "they will take a few years" to be marketed.
"The speed of drugs and progress is faster than the administrative needs of countries," Tomás has indicated, who added that "in many diseases, to be able to offer a more optimal treatment, it is necessary to have trials." "Doing good Medicine is very difficult if one is far from doing a part of research," he explained.
In this sense, he emphasized that at the insurer Sanitas, which has "almost 2,800,000 insured," the research activity constitutes "an almost mandatory bet." In his opinion, "what was research 10, 15, or 20 years ago is now almost a clinical necessity," he stated, emphasizing that clinical trials have become "a reality" integrated into care practice.
In the same vein, the co-director —along with Dr. Ángel Aledo Serrano— of the Clinical Neurosciences Institute of the Sanitas Valdebebas Hospital in Madrid, Dr. Víctor Gómez Mayordomo, has explained that the entity develops trials in the field of migraine, for which "there are already precision molecules that target pain pathways to provide a lot of quality of life."
As he detailed, thanks to these studies, patients "probably access drugs five or seven years earlier," while Gutiérrez has summarized that all of this responds to Sanitas's goal of generating "new knowledge to improve diagnoses" and achieving "more effective treatments, with better results for patients."
(There will be an extension)